帕利珠单抗预防严重呼吸道合胞病毒（RSV）疾病的安全性、有效性和耐受性综述。
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.
作者信息
O'Hagan Shaun, Galway Niamh, Shields Michael D, Mallett Peter, Groves Helen E
机构信息
Paediatric Infectious Diseases, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland.
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland.
出版信息
Drug Healthc Patient Saf. 2023 Sep 11;15:103-112. doi: 10.2147/DHPS.S348727. eCollection 2023.
Abstract
Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific "high-risk" populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.
摘要
呼吸道合胞病毒（RSV）是全球范围内导致儿童发病和死亡的主要原因。帕利珠单抗是一种可提供针对RSV的被动免疫的单克隆抗体，目前已获许可用于特定“高危”人群的预防，包括先天性心脏病、支气管肺发育不良和早产。现有研究表明，在这些高危人群中使用帕利珠单抗可降低与RSV相关的住院率。然而，尚未证实帕利珠单抗能降低与RSV相关的死亡率、不良事件或住院时间。在本文中，我们回顾了RSV的管理、帕利珠单抗预防的适应症、这种预防性药物的安全性、成本效益和疗效，以及可能彻底改变未来对这种重要病原体预防的新兴疗法。
相似文献
1
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.帕利珠单抗预防严重呼吸道合胞病毒（RSV）疾病的安全性、有效性和耐受性综述。
Drug Healthc Patient Saf. 2023 Sep 11;15:103-112. doi: 10.2147/DHPS.S348727. eCollection 2023.
2
3
Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.英国婴儿人群使用帕利珠单抗（Synagis）预防呼吸道合胞病毒的成本效果更新分析。
J Med Econ. 2020 Dec;23(12):1640-1652. doi: 10.1080/13696998.2020.1836923. Epub 2020 Oct 27.
4
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.帕利珠单抗用于预防呼吸道合胞病毒感染的产品评价。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2138-2149. doi: 10.1080/21645515.2017.1337614. Epub 2017 Jun 12.
5
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.帕利珠单抗预防儿童严重呼吸道合胞病毒（RSV）感染。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2.
6
Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.帕利珠单抗预防高危婴儿和幼儿呼吸道合胞病毒（RSV）毛细支气管炎的免疫预防作用：亚组分析的系统评价和额外的经济建模。
Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050.
7
8
Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.帕利珠单抗：作为预防严重呼吸道合胞病毒感染药物的应用综述
Paediatr Drugs. 2004;6(3):177-97. doi: 10.2165/00148581-200406030-00004.
9
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.用于降低儿童呼吸道合胞病毒感染风险的单克隆抗体。
Cochrane Database Syst Rev. 2013 Apr 30(4):CD006602. doi: 10.1002/14651858.CD006602.pub4.
10
Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?呼吸道合胞病毒感染的预防（帕利珠单抗）——是否值得？
Ir Med J. 2000 Dec;93(9):284.
引用本文的文献
1
Epidemiological and phylogenetic characterization of human respiratory syncytial virus associated with severe acute respiratory infections in paediatric patients from 2016 to 2023 in Hangzhou, China.2016年至2023年中国杭州儿科患者中与严重急性呼吸道感染相关的人呼吸道合胞病毒的流行病学和系统发育特征
Microb Genom. 2025 Aug;11(8). doi: 10.1099/mgen.0.001484.
2
Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development.肠道病毒A71在体液免疫和疫苗研发方面的重点、挑战及未来机遇
NPJ Vaccines. 2025 Aug 15;10(1):194. doi: 10.1038/s41541-025-01184-z.
3
Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign.尼塞韦单抗的上市后监测：来自西班牙2023 - 2024年呼吸道合胞病毒免疫接种活动的安全性概况及不良事件分析
Vaccines (Basel). 2025 Jun 10;13(6):623. doi: 10.3390/vaccines13060623.
4
Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles.对目前可用的抗呼吸道合胞病毒药物和研究性化合物的见解，重点关注其耐药性概况。
Viruses. 2025 May 30;17(6):793. doi: 10.3390/v17060793.
5
Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models - a comprehensive review.脂质纳米颗粒递送的抗病毒小干扰RNA疗法在动物模型中的临床前测试——综述
Drug Deliv Transl Res. 2025 Feb 25. doi: 10.1007/s13346-025-01815-x.
6
Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.抗呼吸道合胞病毒的疫苗和治疗药物：已解决和未解决的问题
MedComm (2020). 2024 Nov 21;5(12):e70016. doi: 10.1002/mco2.70016. eCollection 2024 Dec.
7
Chronic lung disease of prematurity and bronchopulmonary dysplasia.早产儿慢性肺病和支气管肺发育不良
J Bras Pneumol. 2024 Sep 27;50(4):e20240279. doi: 10.36416/1806-3756/e20240279.
8
The Role of the CX3CR1-CX3CL1 Axis in Respiratory Syncytial Virus Infection and the Triggered Immune Response.CX3CR1-CX3CL1 轴在呼吸道合胞病毒感染和触发免疫反应中的作用。
Int J Mol Sci. 2024 Sep 11;25(18):9800. doi: 10.3390/ijms25189800.
9
Potential Effects on Elderly People From Nirsevimab Use in Infants.在婴儿中使用尼塞韦单抗对老年人的潜在影响。
Open Respir Arch. 2024 Mar 23;6(2):100320. doi: 10.1016/j.opresp.2024.100320. eCollection 2024 Apr-Jun.
本文引用的文献
1
Maternal RSV vaccine: Further analysis is urged on preterm births.孕妇呼吸道合胞病毒疫苗：敦促对早产情况进行进一步分析。
BMJ. 2023 May 10;381:1021. doi: 10.1136/bmj.p1021.
2
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.孕期接种二价融合前F疫苗预防婴儿呼吸道合胞病毒疾病
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
3
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.用于预防婴儿和儿童呼吸道合胞病毒的单克隆抗体：系统评价和网络荟萃分析。
JAMA Netw Open. 2023 Feb 1;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023.
4
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.老年人呼吸道合胞病毒预融合F蛋白疫苗
N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
5
Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.帕利珠单抗预防呼吸道合胞病毒引起的严重下呼吸道感染的有效性和安全性：系统评价。
Am J Perinatol. 2024 May;41(S 01):e1107-e1115. doi: 10.1055/a-1990-2633. Epub 2022 Nov 30.
6
Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.帕利珠单抗被动免疫预防的中度/晚期早产儿呼吸道合胞病毒住院的真实世界研究。
Am J Perinatol. 2022 Dec;39(S 01):S7-S13. doi: 10.1055/s-0042-1757279. Epub 2022 Oct 28.
7
New strategies for the prevention of respiratory syncytial virus (RSV).预防呼吸道合胞病毒（RSV）的新策略。
Early Hum Dev. 2022 Nov;174:105666. doi: 10.1016/j.earlhumdev.2022.105666. Epub 2022 Sep 10.
8
Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis.利巴韦林治疗呼吸道合胞病毒相关感染患者的疗效：系统评价和荟萃分析。
Adv Ther. 2022 Sep;39(9):4037-4051. doi: 10.1007/s12325-022-02256-5. Epub 2022 Jul 25.
9
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计：系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
10
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.尼赛珠单抗预防健康晚期早产儿和足月婴儿 RSV 感染。
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
Zotero 插件